最准的六合彩论坛

XClose

最准的六合彩论坛 Cancer Institute

Home
Menu

Research into childhood cancers awarded innovation funding

18 March 2021

Researchers at 最准的六合彩论坛 and Great Ormond Street Hospital receive 拢1.7million funding for studies on improving outcomes for children with relapsed leukaemia, and identifying new targets to treat rhabdomyosarcoma (RMS) - a skeletal muscle cancer.

Child receiving leukaemia treatment

The Award is a new initiative to support novel and innovative approaches to childhood cancer research.听Co-funded by Cancer Research UK and Children with Cancer UK, five teams of scientists who are leaders in their field have been awarded up to 拢1 million each to delve into the biology of children鈥檚 and young people鈥檚 cancers, with the hope of finding new ways to prevent and treat these complex cancers.

Improving outcomes for children and young people whose ALL relapses after treatment

Marc Mansour, Jack Bartram, Own Williams and David O'Connor group photo at 最准的六合彩论坛 Cancer Institute

One of the studies awarded this 拢1m grant is the REVEALL Study (RElapse-specific therapeutic Vulnerability Evaluation in childhood & young adult ALL). 听This is a joint proposal led by researchers and clinicians from 最准的六合彩论坛 (Cancer Institute and Great Ormond Street Institute of Child Health) and Great Ormond Street Hospital in collaboration with experts from other centres including the Francis Crick Institute and Memorial Sloan Kettering Cancer Center, New York.

Although most children with leukaemia can be cured with standard therapy, treatment can be much more difficult if the disease returns (鈥渞elapses鈥). To address this issue, a nationwide study will be established, recruiting all children in the UK with relapsed leukaemia.

Speaking of the REVEALL study, Dr David O'Connor said:听鈥淭hrough the analysis of patient samples we will characterise the leukaemia in unprecedented detail, uncovering the cancer鈥檚 genetics and sensitivities to different treatments. This form of personalised medicine will guide which treatments the patients receive, giving them the best chance of survival. We believe our approach will provide direct benefit to children with otherwise untreatable leukaemia. In addition, the wealth of data will provide a key resource for other researchers working on leukaemia, deciphering key mechanisms driving resistance, identifying predictive indicators, commonly called biomarkers, for treatment selection and uncovering new targets for drug development.鈥


Identifying new targets to treat rhabdomyosarcoma (RMS), a skeletal muscle cancer, by investigating its foetal origins听

Karin Straathof working in the lab

Another听study looks at the biology of RMS, which is largely unexplored, but is thought to originate from cells in the foetus that develop incorrectly. Some of these cells persist in children with RMS when usually they wouldn鈥檛. Dr Sam Behjati at the Wellcome Sanger Institute, and Dr Karin Straathof at 最准的六合彩论坛 GOS ICH/GOSH, want to understand why this happens by building a cell 鈥榓tlas鈥 鈥 a complete guide to the cells that form RMS. They hope that understanding how RMS develops will help bring to light new targets for treatment.

Speaking of the study, Dr Karin Straathof said:听鈥淲hile families of children diagnosed with cancer often ask this question, we do not yet know how cancers like rhabdomyosarcoma develop. By building a detailed map of this cancer and comparing this with what happens during normal development we will get a better understanding of the root of rhabdomyosarcoma. And importantly these insights will provide us with clues of how to develop new treatments.鈥

Dr Sam Behjati said: 鈥淎lthough treatments have dramatically improved over the past few decades, children continue to suffer from rhabdomyosarcoma, with few novel treatment approaches in sight. Moreover, survivors often experience lifelong adverse effects from treatment. I hope that our research will ultimately translate into benefits for children with rhabdomyosarcoma, in particular, better treatments."听


Further information

CRUK and Children with Cancer logo lockup